OSE Immunotherapeutics to Present at 4th Annual Immuno-Oncology: BD&L and Investment Forum Forum to be held in Chicago, IL, on June 1, 2018

Alexis Peyroles, chief executive officer, will provide a Company update, including recent accomplishments and future plans, at the upcoming 4th Annual Immuno-Oncology: BD&L and Investment Forum…

 

OSE Immunotherapeutics Presents New Data on OSE-127 at the American Association of Immunologists (AAI) Annual Meeting

OSE-127 significantly decreases inflammation in colon biopsies from patients with inflammatory bowel diseases…

 

OSE Immunotherapeutics Receives the Euronext Tech40 Label

Wanting to give more prominence to outstanding listed Tech companies, every year Euronext grants its Tech40 label…

 

OSE Immunotherapeutics Announces Evolution in Company’s Board of Directors and Management

Dominique Costantini, MD, Appointed as Chairman of Company’s Board of Directors, Alexis Peyroles Appointed as Chief Executive Officer…

 

Partnership with Boehringer Ingelheim – Conference of April 5, 2018: Access to the audio playback and presentation

Access to the audio playback

Access to the presentation

 

OSE Immunotherapeutics to Host Conference Call on April 5, 2018 to Discuss Boehringer Ingelheim Global Immuno-Oncology Partnership

Conference audio/web details – Thursday, April 5th @ 6:00 PM CET…

 

 

 

Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors

Boehringer Ingelheim and OSE Immunotherapeutics enter into a global license and collaboration agreement in immuno-oncology to develop OSE-172, a novel checkpoint inhibitor antibody targeting myeloid lineage cells…

OSE Immunotherapeutics: 2017 Annual Results and Clinical Advances of its Proprietary and Partnered Products – Key Clinical Portfolio Development Progress Planned for 2018

2017 Annual Results and Clinical Advances of its Proprietary and Partnered Products…

 

 

 

OSE Immunotherapeutics Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco on April 8-10, 2018

Dominique Costantini, CEO of OSE Immunotherapeutics, will provide an overview of the Company’s business during the live presentation…

 

OSE Immunotherapeutics to Present New Data on OSE-172 at American Association for Cancer Research Annual Meeting 2018, Chicago, April 14-18

OSE-172, SIRPa Antagonist, Prevents Metastasis Spread in Aggressive Cancer Models; Decreases Tumor Growth and Suppressive Function of Tumor Myeloid Cells, MDSC and M2 Macrophages, in Various Cancers Models; Potentiates Dendritic Cell Tumor Antigen Cross-Presentation Increasing T-Cell Specific …

 

 

  • Activation.